日程嘉宾
苏岭博士在药品法规及注册审评管理、新药研发策略和管理、临床研究、药物安全和药物警戒、药物流行病学等领域拥有丰富经验。曾任职于原卫生部药政管理局和美国FDA，担任药物信息协会 (DIA) 全球理事会主席等职。先后在默沙东、罗氏、惠氏、诺华等多家跨国制药企业从事临床研究和药物研发的高级管理工作
王辰 院士
主任医师，教授， 中国工程院院士 中国医学科学院北京协和医学院院校长
Chinese Academy of Medical Sciences and Peking Union Medical College
Academician of the Chinese Academy of Engineering
Director, National respiratory clinical research center
Leader, National Key Disciplines for Respiratory Medicine
Prof. Wang has long been engaged in clinical practice, teachings and research on respiratory problems such as pulmonary embolism, pulmonary hypertension, respiratory failure, pulmonary heart disease, chronic obstructive pulmonary diseases (COPD, Chronic Bronchitis Emphysema), new respiratory infectious diseases and tobacco epidemiology. He has achieved many important innovations including thrombolysis therapy and sequential mechanical ventilation, which have been adopted to the international treatment guidelines. He is in charge of multiple national research projects and international programs.
Prof. Wang has published more than 100 articles in international authoritative medical journals, such as the New England Journal of Medicine, The Lancet and Annals of Internal Medicine (Ann Intern Med). He has been honored as the Second Prize (three times), the First Prize (once) and the Special-class Prize (once) of the National Science and Technology Progress Award, and has received the Scientific and Technological Progress Award of the Ho Leung Ho Lee Foundation and the Outstanding Contribution Award for Tobacco Control of WHO, etc.
Prof. Wang has made impressive progress in disciplinary construction and hospital management when he served as senior administrator of medical institutions including the Beijing Chao-Yang Hospital, Beijing Hospital and the China-Japan Friendship Hospital. He once worked as the Deputy Director-General of the Department of Health Sciences, Technology and Education of China‘s National Health and Family Planning Commission (NHFPC), presiding over the department by promoting medical education and research at the national level.
王辰 院士
主任医师，教授，中国工程院院士
中国医学科学院北京协和医学院院校长
王辰，呼吸病学与危重症医学专家。主任医师，教授，中国工程院院士。中国医学科学院北京协和医学院院校长。国家呼吸临床研究中心主任。中国医院协会副会长，中国医师协会副会长兼呼吸医师分会会长，中华医学会呼吸病学分会荣誉主任委员，国家毕业后医学教育专家委员会副主任委员。世界卫生组织慢性非传染性疾病专家委员会委员，世界卫生组织戒烟与呼吸疾病预防合作中心主任，英国帝国理工学院医学部荣授院士。Chinese Medical Journal总编辑，Clinical Respiratory Journal主编。
长期从事肺栓塞与肺动脉高压、呼吸衰竭与呼吸支持技术、新发呼吸道传染病、慢性阻塞性肺疾病、烟草病学等领域的医疗、教学与研究工作。长于呼吸疑难病与危重症诊治。做出序贯机械通气、肺栓塞减量溶栓疗法、确证中药对流感疗效等多项创新并进入国际指南，指导改善临床实践。承担国家及国际重要研究项目10余项。在New Engl J Med、Lancet等国际权威期刊发表论文100余篇。主编专著《肺栓塞》《呼吸支持技术》与国家规划教材《内科学》《危重症医学》等10余部。获国家科技进步奖二等奖3项、一等奖1项、特等奖1项。获何梁何利基金科学与技术进步奖，世界卫生组织控烟杰出贡献奖。
具有中日医院、北京医院和北京朝阳医院3家大型综合医院和北京呼吸疾病研究所的领导和管理工作经验，在学科建设和医院管理发展上取得显著业绩。曾主持原卫生部和国家卫生计生委科技教育司工作，推行建立国家住院医师规范化培训制度和专科医师规范化培训制度，倡导推动国家临床医学研究体系建设和能力提升。
吴文达 医学博士
比尔及梅琳达·盖茨基金会北京代表处健康创新与合作副主任
Dr. Alexander Ng leads a team that works to build health partnerships with key
stakeholders in China, including the Chinese government, private sector and NGOs. The
goal is to identify, develop and deliver high-quality, low-cost health products (drugs,
vaccines, biologics, diagnostics) for use in developing countries to tackle endemic diseases
and other urgent health needs. Alex’s team also works with local partners to design and
deliver programs that address domestic health challenges such as tuberculosis, HIV/AIDS
and poverty.
Alex joined the foundation in 2015 after 9 years at McKinsey & Co., where he was an
Associate Partner and co-led McKinsey’s Healthcare Practice and Corporate Finance
Practice in Greater China, where he served public, private and social sector clients on
strategy, health system reform, operations transformation and investments.
Alex completed his undergraduate and medical studies at the University of Auckland, New
Zealand, and a postgraduate diploma in Health Informatics at the University of Otago,
New Zealand. From 2004 to 2005 he served as Chief Resident at Auckland’s Middlemore
Hospital – a tertiary referral hospital for South Pacific, before completing an MPH in
Health Policy and Management at the Harvard School of Public Health.
Since 2010, Alex has been an Honorary Professor with the Faculty of Medicine, University
of Hong Kong and has been a Council Member of Hong Kong Council of Smoking and
Health since 2012.
Bruce REED 博士
美国国立卫生研究院科学审查中心开发和老龄化部，神经科学处处长
Bruce Reed has joined the Center for Scientific Review as director of its Division of Neuroscience, Development and Aging. He comes from the University of California, Davis, where he has been a professor of neurology and associate director of its NIH-funded Alzheimer’s Disease Center as well as a neuropsychologist at Veterans Affairs Northern California in Martinez.
“The search committee and I were compelled by Dr. Reed’s impressive expertise and experience,” said CSR director Dr. Richard Nakamura. “He is a well-published neuroscientist in a variety of fields including Alzheimer’s and he has significant management experience.” Nakamura noted that Reed also brings valued extramural perspectives, including those of a long-time reviewer. He also has served as chair of CSR study sections on adult psychopathology and disorders of aging and clinical neuroscience and neurodegeneration.
Reed earned his Ph.D. from the State University of New York at Stony Brook School of Medicine and he did his postdoctoral training at Braintree Hospital in Massachusetts, in conjunction with Tufts New England Medical College and Boston University Medical College.
His research has expanded our understanding of risk factors—especially vascular factors— that accelerate cognitive decline in old age, as well as factors such as cognitive reserve that protect against decline. He is an expert in neuropsychological and brain imaging methods and he has extensive experience in the use of demographically diverse aging cohorts to better understand the heterogeneity of cognitive aging.
富永俊義 博士
ICH Assembly主席 欧盟药品委员会资深专家
Dr. Tominaga is Associate Executive Director (for International Programs) in PMDA, Japan. He supervises the overall strategy and
conduct of international operations by PMDA.
He joined Japan’s MHLW after he acquired his Ph. D. degree in 1987 from Faculty of Pharmaceutical Sciences, the University of
Tokyo. As a career official, he has experienced positions dealing with narcotics control, R&D enhancement, NDA review, and drug pricing. His international experience includes two-year graduate study at Harvard School of Public Health (1990-1992), three-year stay in Vienna as a diplomat (1999-2002), and one-year stay at FDA, US as an adviser to Director of OIP (2008-2009).
Dr. Tominaga was formerly Director of the Office of International Programs (OIP) of PMDA (2009-2012), he returned to PMDA in August 2014 after he worked at the Osaka City University Medical School as Professor and Director of the Food and Drug Evaluation Center(2012-2014).
Edward COX 医学博士
美国FDA药物评价和研究中心抗菌产品办公室主任
Dr. Edward Cox is Director of the Office of Antimicrobial Products, where he has served since 2007. As Director for the Office of Antimicrobial Products, Dr. Cox oversees the review, approval and safety of antimicrobial (antibacterial, antiviral, antifungal, and antiparasitic) drugs, ophthalmic drugs, and immunosuppressive agents for patients who have received solid organ transplants. Dr. Cox has worked extensively on the science and design of clinical trials for evaluating antimicrobial drugs.
Dr. Cox received his M.D. from the University of North Carolina School of Medicine. He completed an internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania and an Infectious Disease fellowship at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. He also holds a Masters of Public Health Degree from the Johns Hopkins School of Hygiene and Public Health. He joined FDA in 1998.
Agnes SAINT-RAYMOND 医学博士
EMA国际事务及Portfolio Board负责人
Joined French Agency for medicines (now ANSM) in 1995 as Head of a Pharmaco-Toxico-Clinical Assessment Unit. Joined EMA in 2000. Head of Special Areas for Human Medicines (Paediatric Medicines, Orphan Medicines, Scientific Advice, SME Office, and Scientific Support & Projects) until 2013. Head of Portfolio Board since Aug 2013. Head of International Affairs (a.i.) since Nov 2016.
